PCRX vs SN.L
PCRX: Pacira BioSciences is a non-opioid pain management company commercializing injectable, device, and gene therapy treatments for postsurgical and osteoarthritis pain. SN.L: A global medical technology leader focused on restoring patient mobility through advanced orthopedic, sports medicine, and wound care solutions.
Side-by-side fundamentals
| Metric | PCRX | SN.L | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $24.67 | £10.74 | |
| Market cap as of 2026-08-24 | $983M | n/a | |
| P/E as of 2026-08-24 | 62.71 | n/a | |
| PEG as of 2026-08-24 | 20.37 | n/a | |
| Net margin as of 2026-08-24 | +2.0% | n/a | |
| Gross margin as of 2026-08-24 | +79.2% | n/a | |
| Operating margin as of 2026-08-24 | +1.1% | n/a | |
| ROE as of 2026-08-24 | +2.1% | n/a | |
| ROA as of 2026-08-24 | +1.2% | n/a | |
| Debt / equity as of 2026-08-24 | 0.54 | n/a | |
| Revenue growth (YoY) as of 2026-08-24 | +5.7% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +2.9% | n/a | |
| Beta as of 2026-08-24 | 0.23 | n/a | |
| 1-year return as of 2026-08-21 close | -2.8% | -22.8% | PCRX higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.